Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- GoogleOur new health and safety tools are live in the Google Health app.Companies: Alphabet Inc.Pixel Watch users can explore the new health and safety tools in the Google Health app.
- OracleOracle Health and ID.me Team to Simplify Secure Access to Health DataCompanies: Oracle CorporationOracle Health and Life Sciences Summit – Oracle Health and ID.me today announced a collaboration to integrate ID.me's trusted digital identity...
- Fuse Oncology, Inc.Fuse Oncology Extends FuseRx Beyond the Physician to the Full Radiation Oncology Care TeamBeyond treatment intent, the complete clinical workflow will include tools for the physician, physicist, dosimetrist, therapist and nurse. It builds on collaboration with the University of Michigan and Cone Health, part of Risant Health. BOONE, N.C., Sept. 24, 2026 -- Fuse...
- AssurityAssurity launches streamlined new Quick Issue Critical Illness Insurance for fast supplemental health salesAssurity Life Insurance Company introduced Quick Issue Critical Illness Insurance – fast, affordable protection designed to help customers manage the financial impact of serious health events. With streamlined coverage for the most common...
- Jiro HealthPrivate Practices Would Bear 80% of the Nearly $1B Impact of CMS's Modifier 25 ProposalJiro's analysis of Medicare claims finds the impact concentrated in six specialties, with dermatology alone accounting for nearly $400 million. — A new analysis from Jiro Health estimates that a proposed change to Medicare payments involving...
- Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual MeetingAnavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden.
- Form 8.3 - Advanced Medical Solutions Group plc - Octopus InvestmentsFORM 8.3
- SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD TherapyPrestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute kidney injury (AKI)
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot UlcersInitiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 -- Lakewood-Amedex...
- Solenic Medical Appoints Daniel Hawkins as Chairman of the BoardAccomplished Medical Device Executive and Board Leader Brings Deep Industry Experience as Solenic Enters its Next Phase of Clinical and Strategic Growth
- Boehringer Ingelheim and WHO Foundation launch global collaboration to close the gap in obesity and metabolic healthCompanies: Boehringer IngelheimIngelheim, Germany - Boehringer Ingelheim and the WHO Foundation today announced a three-year collaboration to accelerate progress on obesity and its related metabolic conditions in resource-limited settings.
- Lupus Nephritis Pipeline 2026: Targeted Therapies and Clinical Innovation Drive New Treatment and Market Opportunities Through the Forecast PeriodLupus nephritis R&D is shifting toward targeted B-cell, complement, and off-the-shelf cell therapies, opening partnership and licensing opportunities across novel treatment platforms